Valneva reserved enough CpG 1018 to support 40 million additional doses of VLA2001 that have been ordered by the U.K. government. As a result of the U.K. contract, Valneva has now reserved quantities of CpG 1018 sufficient to support production of 100 million doses of VLA2001 in 2021, according to Dynavax.

In other Dynavax news, the company said that it signed a deal with CEPI to supply CpG 1018 for approved COVID-19 vaccines developed by CEPI grantees.

Under the terms of the deal, CEPI will provide a forgivable loan of up to $99 million for manufacturing of CpG 1018 with the potential to support hundreds of million doses of COVID-19 vaccines for delivery in 2021 through the global COVID-19 vaccine supply initiative COVAX. Dynavax would sell the reserved CpG 1018 under separate commercial supply agreements made directly with CEPI grantees, according to the company.

Medigen Vaccine, Dynavax begin phase II trial for subunit COVID-19 vaccine
Medigen Vaccine Biologics and Dynavax Technologies have dosed the first participant in a phase II clinical trial evaluating Medigen's COVID-19 vaccine...

Pfizer, BioNTech finalize supply deal with EU for COVID-19 vaccine
Pfizer and BioNTech, developers of BNT162b2, a messenger RNA-based SARS-CoV-2 vaccine candidate, have reached an agreement with the European Commission...

If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...

Dynavax partners on Valneva's SARS-CoV-2 vaccine candidate
Dynavax will supply its CpG 1018 adjuvant for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001, as part of a commercial partnership.